top of page

BackTable / VI / Tool

ALBI Score Calculator

The ALBI score (Albumin-Bilirubin score) is a valuable tool for assessing liver function in patients with chronic liver disease or hepatocellular carcinoma. Unlike traditional scoring systems, such as the Child-Pugh score, the ALBI score relies solely on objective laboratory values, making it a simpler and more precise measure. BackTable’s ALBI score calculator simplifies the process by automating calculations and minimizing errors. Clinicians can input the required parameters (bilirubin and albumin levels) into the calculator, and it instantly provides the ALBI score.

ALBI Score Calculator

ALBI Score Calculator

Bilirubin (mg/dL):

Albumin (g/dL):

Calculate

Value

Value

Value

What is an ALBI Score?

The ALBI score evaluates liver function by incorporating two critical laboratory parameters: serum albumin (g/L) and bilirubin levels (μmol/L). It uses the formula:

ALBI = (log10 bilirubin × 0.66) + (albumin × −0.085)

This scoring method eliminates subjectivity by relying solely on measurable values, allowing clinicians to make more consistent assessments. By categorizing patients into grades, the ALBI score provides a clear picture of liver function. This has significant implications for patient care, particularly in treatment planning for hepatocellular carcinoma and other liver-related conditions.

ALBI Score Interpretation

The ALBI score is categorized into three grades, each with distinct clinical implications:

Grade: 1
• ALBI Score <= -2.60
• Median Survival: 18.5 - 85.6 months
• Best prognosis

Grade: 2
• ALBI Score > -2.6 to <= –1.39
• Median Survival: 5.3 - 46.5 months

Grade: 3
• ALBI Score >= -1.39
• Median Survival: 2.3 - 15.5 months
• Worst prognosis

These grades are critical in guiding treatment decisions and assessing patient prognosis. For example, patients with a Grade 1 score may tolerate aggressive treatments better than those with Grade 3.

ALBI Score Clinical Applications

The ALBI score is widely used in clinical settings for:
• Assessing liver function: It provides a reliable measure of hepatic reserve in patients with chronic liver disease.
• Predicting outcomes: Particularly in hepatocellular carcinoma, the ALBI score helps estimate survival rates and response to treatments.
• Treatment planning: By categorizing patients based on liver function, clinicians can tailor interventions to minimize risks and optimize outcomes.

Learn more on the BackTable VI Podcast

BackTable is a knowledge resource for physicians by physicians. Get practical advice on the ALBI Score Calculator and how to build your practice by listening to the BackTable VI Podcast, reading exclusing BackTable Articles, and following the work of our Contributors.

Pressure-Directed Therapy in Y90
Ep 16 Pressure-Directed Therapy in Y90 with Dr. Charles Nutting and Dr. Nainesh Parikh
00:00 / 01:04

References

[1] Pugh, R. N. H., et al. "Prognostic factors in cirrhosis." Gut, 1973.
[2] Johnson, P. J., et al. "Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade." Journal of Clinical Oncology, 2015.
[3] Chan, A. W. H., et al. "Development of a novel ALBI-based nomogram for hepatocellular carcinoma prognosis." Clinical Cancer Research, 2016.
[4] Bruix, J., et al. "Management of hepatocellular carcinoma." Hepatology, 2011.
[5] Kudo, M., et al. "ALBI grade and prognosis in hepatocellular carcinoma." Liver Cancer, 2017.

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

Related Podcasts

Complex HCC Patients & The "Grey Zone": What To Do When You Don’t Know What To Do with Dr. Adam Burgoyne, Dr. Zach Berman, Dr. Kirema Garcia-Reyes and Dr. Lingling Du on the BackTable VI Podcast)
Curative Intent Therapies for HCC: Today & Tomorrow with Dr. Kirema Garcia-Reyes, Dr. Kevin Burns, Dr. Sabeen Dhand and Dr. Zach Berman on the BackTable VI Podcast)
Combination Therapy and Clinical Trials for Advanced HCC: What They Really Mean with Dr. Lingling Du, Dr. Jonathan Mizrahi, Dr. Adam Burgoyne and Dr. Zach Berman on the BackTable VI Podcast)
How to Simplify Dosing: Understanding Y90 Dosimetry from Simple to Complex with Dr. Tyler Sandow, Dr. Sabeen Dhand, Dr. Zach Berman, Dr. Kirema Garcia-Reyes and Dr. Sid Pdia on the BackTable VI Podcast)
Surviving Cancer: A Patient's Radioembolization Journey with Suzanne Martin on the BackTable VI Podcast)
Multidisciplinary HCC Care: Improving the Patient Experience with Combined Clinics with Dr. Tyler Sandow, Dr. Jonathan Mizrahi, Dr. Steven Young and Deondra Bonds-Adams on the BackTable VI Podcast)

Articles

The Future of Radiation Segmentectomy: New Tech, Tumor Markers & Indications

The Future of Radiation Segmentectomy: New Tech, Tumor Markers & Indications

Planning for HCC Radiation Segmentectomy: Mapping, Margins & Dosage

Planning for HCC Radiation Segmentectomy: Mapping, Margins & Dosage

Hepatocellular Carcinoma in Practice: Optimizing Workflows & Treatment Decisions

Hepatocellular Carcinoma in Practice: Optimizing Workflows & Treatment Decisions

Current Practices In Combination Therapy for Hepatocellular Carcinoma

Current Practices In Combination Therapy for Hepatocellular Carcinoma

Topics

bottom of page